Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine November 2011, 52 (11) 11A-12A;
  • Article
  • Info & Metrics
  • PDF
Loading

Future of CXCR4 agents: Woodard and Nimmagadda review recent developments in chemokine receptor 4–based imaging agents and their potential roles in molecular diagnosis and treatment of cancer.Page 1665

99mTc-annexinA5 and therapy timing: Lewis offers perspectives on the development and current status of anti-vascular endothelial growth factor therapy and previews a related article in this month's JNM that focuses on vascular normalization and apoptosis.Page 1670

PET costs in metastatic infection: Vos and colleagues present a cost effectiveness analysis of the introduction of 18F-FDG PET/CT in patients with gram-positive bacteremia, with findings on the benefits of early detection.Page 1673

68Ga-DOTATATE uptake and octreotide: Haug and colleagues assess the results of treatment with a long-acting somatostatin analog on 68Ga-DOTATATE binding in neuroendocrine tumors.Page 1679

Treatment response to erlotinib: Benz and colleagues determine whether early changes in tumor uptake of 18F-FDG on PET can predict progression-free and overall survival in patients with non–small cell lung cancer treated with erlotinib.Page 1684

Figure

PET vs. CT NSCLC tumor delineation: Hatt and colleagues investigate the relationship between CT- and 18F-FDG PET–based tumor volumes in non–small cell lung cancer and the effects of tumor size and uptake heterogeneity on PET uptake assessment.Page 1690

Figure

Carotid PET/CTA histologic validation: Menezes and colleagues combine PET, CT angiography, and immunohistochemistry to explore the contributing roles of inflammation, angiogenesis, and calcification in both plaque vulnerability and stability in patients undergoing carotid endarterectomy.Page 1698

Figure

Coronary structure and cardiac perfusion: Liga and colleagues use PET and CT to investigate the effects of coronary luminal narrowing, structural abnormalities of the coronary arterial wall, and cardiovascular risk factors on regional and global myocardial blood flow reserve.Page 1704

18F-FDG uptake and eosinophils in asthma: Harris and colleagues report on research to determine whether 18F-FDG uptake rate on PET can serve as a biomarker of eosinophilic inflammation and local lung function.Page 1713

Figure

Repeated 188Re-HEDP in bone metastases: Biersack and colleagues describe a study comparing the effects of single and multiple administrations of this radiolabeled agent on palliation and survival in prostate cancer patients presenting with more than 5 skeletal metastases.Page 1721

Multilesion molecular imaging: Fox and colleagues propose a 5-step, practical, standardized approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.Page 1727

Figure

Brain amyloid imaging: Rowe and Villemagne offer an educational overview of the role of biomarkers in more accurate and earlier diagnosis of Alzheimer disease, with a special focus on the status and potential of PET in imaging brain β-amyloid plaques.Page 1733

NanoPET/CT evaluation: Szanda and colleagues report on performance evaluation of the PET component of the NanoPET/CT commercial small-animal imaging system according to National Electrical Manufacturers Association standards.Page 1741

Figure

Precision and sensitivity of 18F PET: Siddique and colleagues evaluate several methods of analyzing 18F-fluoride PET dynamic spine scans to identify the approach that requires the smallest sample size to detect statistically significant responses to treatment.Page 1748

Combination therapy for thyroid cancer: Kim and colleagues research the effects of a lentiviral small-hairpin RNA targeting hexokinase II and human sodium iodide symporter gene expression combined with radioiodine treatment in anaplastic thyroid cancer in an animal model.Page 1756

Figure

Cerenkov imaging and PET: Robertson and colleagues compare PET and Cerenkov luminescence imaging (both with 18F-FDG) assessments of a phase 2 oncology therapeutic agent in small-animal models of diffuse large B-cell lymphoma.Page 1764

PET and macrophages in peritoneal cancer: Cottone and colleagues use PET to evaluate and follow the contribution of tumor-associated, inflammatory infiltrating macrophages in tumor progression in a mouse model of peritoneal cancer.Page 1770

Intraoperative VEGF and HER2 imaging: Terwisscha van Scheltinga and colleagues apply antibody-based tumor detection to intraoperative optical imaging in mice.Page 1778

Identifying the normalization window: Vangestel and colleagues study the efficacy of an antihuman vascular endothelial growth factor antibody with or without irinotecan during chemotherapy delivery in colorectal cancer xenografts and focus on the importance of administration timing.Page 1786

MMP imaging and plaque heterogeneity: Razavian and colleagues explore an in vivo imaging approach for monitoring matrix metalloproteinase activation in atherosclerotic mouse aorta and use it to assess responses to dietary modification.Page 1795

CXCR4 PET using 68Ga-CPCR4-2: Gourni and colleagues evaluate the imaging and biokinetic characteristics of a small and optimized radiolabeled peptide that targets human CXCR4 receptor expression.Page 1803

Serotonin 5-HT7 receptor neuroimaging: Lemoine and colleagues conduct studies comparing 4 radiolabeled structural analogs of a specific brain serotonin receptor antagonist and describe successful PET imaging in animal models.Page 1811

Figure

TF antigen imaging: Kumar and colleagues synthesize and evaluate the properties of a 64Cu-radiolabeled Thomsen–Friedenreich antigen–specific peptide derived from bacteriophage display for human breast tumor targeting and PET imaging in xenografted mice.Page 1819

Figure

Radiation damage after micro-CT: Kersemans and colleagues elucidate relationships among radiation dose, biologic damage, and image quality to determine whether CT can be used without significantly compromising radiotherapy and tumor development studies.Page 1827

ON THE COVER

Figure

Cerenkov luminescence imaging is an emerging technique that combines aspects of both optical and nuclear imaging. An antitumor study in this issue of JNM has confirmed the dynamic sensitivity of this new modality and its correlation with PET findings. The technique provides a preclinical alternative to expensive PET instrumentation that should allow for higher cost-to-return benefits in the drug discovery process. See page 1767.

  • © 2011 by Society of Nuclear Medicine
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (11)
Journal of Nuclear Medicine
Vol. 52, Issue 11
November 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Nov 2011, 52 (11) 11A-12A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Nov 2011, 52 (11) 11A-12A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • ON THE COVER
  • Info & Metrics
  • PDF

Related Articles

  • Cost-Effectiveness of Routine 18F-FDG PET/CT in High-Risk Patients with Gram-Positive Bacteremia
  • 18F-FDG Uptake Rate Is a Biomarker of Eosinophilic Inflammation and Airway Response in Asthma
  • 64Cu-Labeled Peptide for PET of Breast Carcinomas Expressing the Thomsen-Friedenreich Carbohydrate Antigen
  • The Precision and Sensitivity of 18F-Fluoride PET for Measuring Regional Bone Metabolism: A Comparison of Quantification Methods
  • Looking Through the Vascular Normalization Window: Timing Antiangiogenic Treatment and Chemotherapy with 99mTc-Annexin A5
  • Micro-CT for Anatomic Referencing in PET and SPECT: Radiation Dose, Biologic Damage, and Image Quality
  • PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent
  • Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
  • 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
  • Investigating Vulnerable Atheroma Using Combined 18F-FDG PET/CT Angiography of Carotid Plaque with Immunohistochemical Validation
  • National Electrical Manufacturers Association NU-4 Performance Evaluation of the PET Component of the NanoPET/CT Preclinical PET/CT Scanner
  • Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies
  • CXCR4-Based Imaging Agents
  • Structural Abnormalities of the Coronary Arterial Wall—in Addition to Luminal Narrowing—Affect Myocardial Blood Flow Reserve
  • Atherosclerosis Plaque Heterogeneity and Response to Therapy Detected by In Vivo Molecular Imaging of Matrix Metalloproteinase Activation
  • 99mTc-(CO)3 His-Annexin A5 Micro-SPECT Demonstrates Increased Cell Death by Irinotecan During the Vascular Normalization Window Caused by Bevacizumab
  • Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
  • Multimodal Imaging with 18F-FDG PET and Cerenkov Luminescence Imaging After MLN4924 Treatment in a Human Lymphoma Xenograft Model
  • Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT
  • Evaluation of the Role of Tumor-Associated Macrophages in an Experimental Model of Peritoneal Carcinomatosis Using 18F-FDG PET
  • Brain Amyloid Imaging
  • Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT7 Receptor Neuroimaging: Toward the First PET Radiotracer
  • Combined RNA Interference of Hexokinase II and 131I-Sodium Iodide Symporter Gene Therapy for Anaplastic Thyroid Carcinoma
  • Impact of Tumor Size and Tracer Uptake Heterogeneity in 18F-FDG PET and CT Non–Small Cell Lung Cancer Tumor Delineation
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire